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864Objective: The goal of this study was to quantify the net increase in resource use associated with complications
after isolated mitral valve surgery.
Methods:Deidentified patient-level claims data on a random sample of mitral valve operations performed in the
United States from January 1, 2006, to December 31, 2007, were obtained from the National Inpatient Sample
(n ¼ 16,788). Patients with major concomitant cardiac procedures were excluded from the analysis for a net
sample size of 6297 patients. Risk-adjusted median total hospital costs and length of stay were analyzed by ma-
jor complications, including pneumonia, sepsis, stroke, renal failure requiring hemodialysis, cardiac tamponade,
myocardial infarction, gastrointestinal bleed, and venous thromboembolism.
Results: There were a total of 1323 complication events that occurred in 1089 patients. The most common com-
plication was pneumonia (n ¼ 346, 5.5%), which was associated with a $29,692 increase in hospital costs and
a 10.2-day increase in median length of stay (P<.001). The most costly complication was cardiac tamponade,
which resulted in an increase in hospital cost of $56,547 and an increase in length of stay of 19.3 days (P<.001).
There was a stepwise association between the hospital costs and length of stay and the number of complications
per patient (P<.001). There was also a significant association between the discharge location and the occurrence
of a complication, with 25% more patients who underwent routine home discharge when there were no
complications (P<.001).
Conclusions: In patients undergoing isolated mitral valve surgery, postoperative complications were associated
with significant increases in mortality, hospital costs, and length of stay, as well as with discharge location. With
growing national attention to improving quality and containing costs, it is important to understand the nature and
impact of complications on outcomes and costs. (J Thorac Cardiovasc Surg 2012;143:864-72)Among patients undergoing mitral valve surgery (MVS),
significant improvements in outcomes have been observed
nationally over the past decade.1,2 Data from large national
registries have demonstrated that length of stay and
perioperative morbidity and mortality have achieved
acceptably low levels.3,4 These improvements in outcomes
have occurred in the face of an increased frequency of
comorbidities among patients presenting for MVS,
including an increased prevalence of diabetes, hypertension,
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The Journal of Thoracic and Cardiovascular SurgUS population, patients will continue to face significant peri-
operative risk after MVS.
It is well recognized that postoperative complications are
associated with increased mortality, prolonged hospital
stay, and greater resource use.6 However, detailed data re-
garding the clinical and economic impact of postoperative
complications, particularly after valvular surgery, remain
scarce.7 Availability of this information could be used to
target further quality improvement efforts, which may sig-
nificantly improve outcomes for patients and cost-
containment efforts in an era when cost-effectiveness is at
the forefront of healthcare policy initiatives.8
The purpose of this study was to characterize the impact
of postoperative complications on clinical outcomes, such
as mortality and discharge disposition, and the net increase
in resource use, including in-hospital cost and length of
stay, in a national cohort of patients undergoing isolated
MVS.METHODS AND MATERIALS
Data Source and Study Population
The Nationwide Inpatient Sample (NIS), which is sponsored by the
Agency for Healthcare Research and Quality, Healthcare Cost and Utiliza-
tion Project, was used to identify patient discharges related to MVS thatery c April 2012
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The NIS provides only deidentified patient claims data, and thus this anal-
ysis qualified for institutional review board exception. The NIS is a 20%
sampling of abstracted discharge data from a national survey of all non-
federal acute care hospitals in the United States and contains discharge re-
cords from more than 1000 hospitals in 37 states.9
The NIS contains up to 15 procedure codes per patient using the Inter-
national Classification of Diseases, Ninth Revision, Clinical Modification
(ICD-9-CM) procedure code index. MVS was abstracted using ICD-9-
CM codes 35.23, 35.24, and 35.12 in the first, second, or third procedure
code position. For the primary analysis, major concomitant cardiac proce-
dures (coronary artery bypass grafting [CABG], aortic valve surgery,
tricuspid valve surgery, and arrhythmia surgery) were excluded using
appropriate ICD-9-CM codes to study only patients with isolated MVS
(n ¼ 6297) and avoid the potential confounding effect of multiple proce-
dures on resource use. In addition, patients aged less than 18 years were ex-
cluded from the analysis. The NIS does not provide data on repeat
procedures.
Clinical Outcomes and Complications
Major clinical outcomes of interest included length of hospitalization,
in-hospital morbidity, and in-hospital mortality. Given that the NIS in-
cludes data on up to 15 diagnoses per discharge, a focus on specific major
postoperative complications (eg, pneumonia) rather than complication
systems-based categories (eg, respiratory complications) was used to max-
imize specificity of results. Specific major postoperative complications ex-
tracted from the NIS using appropriate ICD-9 codes included pneumonia
(ICD-9-CM codes 480–487); acute renal failure (ICD-9-CM code 584);
septicemia (ICD-9-CM code 038); acute myocardial infarction (ICD-9-
CM code 410); stroke (ICD-9-CM code 436.* and 437.*); cardiac tampo-
nade (ICD-9-CM code 423.3); gastrointestinal bleed (ICD-9-CM codes
530.82, 535.61 and 578.9); and venous thromboembolism (ICD-9-CM
codes 451.* and 453.*). The number of complications per patient was
also analyzed to study the multiplicative effect of complications on
resource use. Last, discharge location was assessed for all patients.
Cost Outcomes
Total billed charges for each hospitalization are present in the NIS data-
set. These data reflect the amount hospitals billed for services rendered
rather than the costs for the specific hospitalization or the amount hospitals
received in payments. Estimated institutional cost data were obtained by
multiplying Healthcare Cost and Utilization Project supplied cost-to-
charge ratios by total charges. Grouped average cost-to-charge ratios areThe Journal of Thoracic and Caa weighted average for the hospitals in the group (defined by state, ur-
ban/rural, investor owned/other, and number of beds) and use the propor-
tion of group beds as the weight for each hospital. Total costs related to
the complication were calculated on the basis of incremental cost multi-
plied by the annual incidence multiplied by a factor of 5 to account for
the 20% sample. All costs were rounded to the nearest $100.
Statistical Analysis of Cost and Clinical End Points
Because medical costs are traditionally right skewed, as costs cannot be
negative, we report median cost in the analysis unless otherwise specified.
For univariate analysis of median cost, results of the Wilcoxon rank-sum
test are reported. To assess the independent effect of complications on total
median hospital costs, multivariable quantile regression using 1000 boot-
strapped iterations was used where the outcome of interest was median
cost. Demographic variables used in multivariable regression included
age and all comorbidities presented in Appendix 1 that had a P value
less than .20 in univariate analysis.
For clinical data, continuous variables were reported as mean  stan-
dard error and compared using the Student t test or Wilcoxon rank-sum
test when noted. Categoric variables were reported as percentages and
compared using the chi-square or Fisher exact test when appropriate.
Median length of stay was reported rather than mean given the potential
for outliers, and risk-adjusted length of stay was analyzed in a similar fash-
ion as cost using multivariable quantile regression with 1000 bootstrapped
iterations. Long-term survival data are not present in the current dataset;
however, in-hospital mortality is coded and reported. Logistic regression
was used to assess the independent effect of the number of complications
on in-hospital mortality. All reported P values are 2-sided. All statistical
analyses were performed using Stata 11 (StataCorp, College Station, Tex).RESULTS
Study Population
From January 1, 2006, to December 31, 2007, there were
16,788 patients in the NIS registry who underwent MVS.
Appendix 2 shows the distribution of repairs, replacements,
and concomitant procedures in the series. There were 6297
(37.5%) isolated mitral valve operations that formed the
study cohort for the primary end points. Among isolated
mitral valve operations, cases were distributed as follows:
mechanical mitral valve replacement (27.5%, n ¼ 1732),
tissue mitral valve replacement (20.4%, n¼ 1282), and mi-
tral valve repair (52.1%, n ¼ 3283). The distribution of
baseline characteristics of the study cohort is summarized
in Table 1. The mean age of patients was 64.6 13.4 years,
the majority of procedures were elective (65.2%,
n ¼ 4103), and the 2 most common comorbidities included
peripheral vascular disease (38.2%, n ¼ 2406) and heart
failure (38%, n ¼ 2396).Clinical Outcomes
The mean and median lengths of stay were 11.6  12.1
and 8 days, respectively, for all isolated mitral valve opera-
tions. The distribution of postoperative complications for
the series is summarized in Table 2. There were a total of
1323 complication events that occurred in 1089 patients.
The 3 most common complications were pneumonia
(5.5%, n ¼ 346), sepsis (4.1%, n ¼ 261), and renal failure
requiring dialysis (3.5%, n ¼ 223). When analyzed by therdiovascular Surgery c Volume 143, Number 4 865
TABLE 1. Baseline demographics and comorbidities of study cohort
Baseline variable
Mean or
frequency
Standard
error or%
Demographics
Age, y 64.6 13.4
Male 3062 48.6
Elective procedure 4103 65.2
Primary payer: Medicare 2781 44.2
Primary payer: Private 2558 40.6
Comorbidities
Peripheral vascular disease 2406 38.2
Heart failure 2396 38.0
Chronic obstructive pulmonary disease 1064 16.9
History of any malignancy 946 15.0
Diabetes mellitus 670 10.6
Chronic kidney disease 571 9.1
Cerebrovascular disease 377 6.0
Previous myocardial infarction 219 3.5
Rheumatologic disease 142 2.3
Diabetes with chronic complications 82 1.3
Moderate or severe liver dysfunction 82 1.3
Peptic ulcer disease 45 0.7
Mild liver dysfunction 30 0.5
Hemiplegia or paraplegia 23 0.4
Metastatic solid tumor 14 0.2
Human immunodeficiency virus 13 0.2
Dementia 2 0.0
TABLE 2. Distribution of in-hospital complication events and number
of complications per patient in addition to discharge disposition
Frequency %
Morbidity events*
Pneumonia 346 5.5
Sepsis 261 4.1
Renal failure requiring hemodialysis 223 3.5
Acute myocardial infarction 172 2.7
Stroke 144 2.3
Gastrointestinal bleed 120 1.9
Venous thromboembolism 49 0.8
Cardiac tamponade 8 0.1
Complications per patient
0 5208 82.7
1 887 14.1
2 171 2.7
3 30 0.48
4 1 0.02
Mortality
In-hospital mortality 253 4.0
Discharge location
Routine discharge 3027 48.1
Home health care 2024 32.1
SNF, ICF, other 929 14.8
Died 253 4.0
Transfer to short-term hospital 36 0.6
Unknown 23 0.4
Against medical advice 5 0.08
SNF, Skilled nursing facility; ICF, intermediate care facility. *Morbidity events reflect
all occurrences of such events in the study cohort rather than the number of events per
patient.
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patients had 1 complication and 2.7% (n¼ 171) had 2 com-
plications. In-hospital mortality for the series was 4.0%
(n ¼ 253); however, among elective patients, the mortality
rate was 2.3%. The 2 most common discharge locations
were routine home discharge (48.1%, n ¼ 3027) and
home with home health care (32.1%, n ¼ 2024). There
was a risk-adjusted stepwise increase in the probability of
in-hospital mortality for 1 (odds ratio [OR], 3.8; confidence
interval [CI], 2.9–5.3, P< .001), versus 2 complications
(OR, 8.5; CI, 5.4–13.4, P<.001), versus 3 complications
(OR, 9.9; CI, 3.8–26.1, P<.001) when compared with no
complications as the reference group.Resource Use
The mean and median cost of hospitalization for the se-
ries was $46,229  $37,193 and $35,446, respectively.
The complications and associated risk-adjusted net increase
in median length of stay and risk-adjusted net increase in
median total hospital cost are summarized in Table 3. Car-
diac tamponade was both the most costly complication, re-
sulting in a median net increase in hospital costs of $56,547
(P<.001), and the complication resulting in the largest net
increase in hospital stay at 19.3 days (P<.001). Of note,
cardiac tamponade was the least frequent complication in
the series, occurring in 0.1% of patients (n ¼ 8). The866 The Journal of Thoracic and Cardiovascular Surgmost common complication in the series was pneumonia
(5.5%, n ¼ 346), and this complication also resulted in
the second largest increase in median net hospital costs
($29,692, P<.001) and the second largest increase in length
of hospitalization (10.2 days, P<.001). Moreover, pneumo-
nia resulted in the single greatest total incremental annual
cost at between $23.9 and $27.5 million. Sepsis and renal
failure requiring dialysis resulted in the second and third
greatest total incremental costs. Given the significant
resource use associated with pneumonia, we also studied
the minor complication of isolated acute pulmonary edema,
which occurred in 5.8% (n¼ 363) of patients. This compli-
cation was associated with an $11,271  855 increase in
total hospital cost (P<.001) and a 2.2  0.3 day increase
in length of stay (P<.001). There was a significant, inde-
pendent association between acute pulmonary edema and
the development of postoperative pneumonia (OR, 3.1;
CI, 2.4–4.0; P<.001).
When analyzed by number of complications per patient,
there was a stepwise association between number of
complications and both total hospital costs and length of
hospitalization (P < .001) (Figure 1). Patients who had
1 complication during their hospitalization had a medianery c April 2012
TABLE 3. Incremental median net increase in hospital cost and length of stay by complication category
Complication category
Median net increase
in hospital cost ($) 95% CI
P
value
Median net
increase in LOS (d) 95% CI
P
value
Incremental cost
incurred annually ($)
Pneumonia 29,692 27,590–31,793 <.001 10.2 9.7–10.7 <.001 23.9–27.5 million
Sepsis 22,404 21,203–23,604 <.001 7.0 6.7–7.3 <.001 13.8–15.4 million
Renal failure requiring hemodialysis 28,336 25,759–30,913 <.001 8.7 8.0–9.4 <.001 14.4–17.2 million
Acute myocardial infarction 20,576 17,672–23,480 <.001 3.5 2.8–4.2 <.001 7.6–10.1 million
Stroke 21,477 17,498–25,456 <.001 9.7 8.5–10.8 <.001 6.3–9.2 million
Gastrointestinal bleed 12,230 8,184–16,277 <.001 6.1 4.9–7.3 <.001 2.5–4.9 million
Venous thromboembolism 25,896 20,934–30,859 <.001 7.3 6.0–8.5 <.001 2.6–3.8 million
Cardiac tamponade 56,547 44,328–68,765 <.001 19.3 16.2–22.3 <.001 0.9–1.4 million
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creased by a median value of $21,000. From 1 to 2 compli-
cations, there was a similar increase of 6 hospital days and
$23,964. From 2 to 3 complications, the length of hospital-
ization increased by 12.5 days, and the cost of hospitaliza-
tion increased by an additional $35,330.
There was a significant association between the discharge
disposition and the occurrence of 1 or more complications
during the index hospitalization (P<.001) (Table 4). Among
patients with no complications, 52.5% (n¼ 2729) were dis-
charged home as a routine discharge, whereas only 27.0%
(n ¼ 298) of such discharges occurred in patients with 1 or
more complication. In addition, patients with no complica-
tions were more likely to use home health care (32.8%,
n ¼ 1703) than patients with complications (29.1%,
n ¼ 321). However, patients with complications were
more likely to be discharged to skilled nursing facilities or
intermediate care facilities (29.1%, n ¼ 321) than patients
without complications (11.7%, n ¼ 608).
Appendix 2 summarizes outcomes of all mitral valve pro-
cedures in the NIS registry during the study period andFIGURE 1. Multiplicative effect of complications on total hospital costs
and length of hospital stay. LOS, Length of stay.
The Journal of Thoracic and Caassociated lengths of stay, total hospital costs, and fre-
quency of in-hospital complications. The 2 procedures asso-
ciated with the highest median length of stay included tissue
mitral valve replacement (MVR)þCABGþaortic valve re-
placement (AVR) and tissue MVRþCABGþAVRþtricus-
pid valve replacement at 14 hospital days each. The median
total hospital costs of all cases was $42,307, with the high-
est cost occurring for tissue MVR þ CABG þ AVR
($66,683), mechanical MVRþ other ($54,100), and tissue
MVRþAVR ($54,646). The highest frequency of complica-
tions occurred in mitral valve repair þ CABG (7.7%,
n ¼ 1290).
DISCUSSION
This analysis describes major complications in a national
sample of patients undergoing isolated MVS and the effect
of these complications on clinical outcomes and resource
use. On the basis of findings in this analysis, complications
related to MVS have a significant adverse impact on both
clinical outcomes and resource use.
In the current healthcare environment, there is increasing
pressure to improve outcomes while containing costs.10,11
Quality measures will influence how healthcare services
are reimbursed in the future. In 2007, the Centers for
Medicaid and Medicare Services (CMS) determined that
it would no longer pay for ‘‘preventable’’ complications.
These never events include, among others, retained
foreign bodies, mediastinitis after CABG, line infections,
pressure ulcers, and air embolism.
In 2011, the CMS issued the Hospital Inpatient Value-
Based Purchasing ProgramFinal Rule.Under this program,
the CMS will provide higher payments to hospitals that
perform well on certain quality measures relating to both
clinical process and patient experience of care. This initia-
tive is intended to help reduce health care costs and reward
hospitals for the quality of care they provide to Medicare
beneficiaries.12 This program will apply to hospital dis-
charges occurring on or after October 1, 2012, with pay-
ments based on whether a hospital meets or exceeds
performance standards. Defined changes in payer strategies
such as these further highlight the need to better understand
processes of care and how to improve them.rdiovascular Surgery c Volume 143, Number 4 867
TABLE 4. Discharge disposition by occurrence of an index
hospitalization complication
Discharge location
No
complications
Any
complication
P
value
Routine home discharge 2729 (52.5%) 298 (27.0%) <.001
Home health care 1703 (32.8%) 321 (29.1%)
SNF, ICF, other 608 (11.7%) 321 (29.1%)
Died 121 (2.3%) 132 (12.0%)
Transfer to short-term hospital 20 (0.38%) 16 (1.5%)
Unknown 10 (0.19%) 13 (1.2%)
Against medical advice 6 (0.12%) 1 (0.09%)
Total 5197 1102
SNF, Skilled nursing facility; ICF, intermediate care facility.
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In this current analysis of patients undergoing isolated
MVS in the United States over a 2-year period, a large pro-
portion of patients presenting for mitral surgery had signif-
icant comorbidities, as suggested by previous authors.5
Peripheral vascular disease and heart failure were present
in 38% of patients undergoing surgery, and chronic obstruc-
tive pulmonary disease was present in 16.9%. With the ag-
ing US population, these frequencies are likely to increase
in the future; however, the demand for quality assurance
and low rates of complications will grow.13
Outcomes
With an overall national in-hospital mortality rate of 4%,
this analysis highlights that, despite its complexity, MVS
can be performed safely. Likewise, no individual complica-
tion occurred inmore than 6% of patients. Nevertheless, ap-
proximately 15% of patients experienced at least 1 of the 8
complications. In-hospital mortality in the subset of patients
in our analysis undergoing elective surgery was similar to
that reported in the most recent analysis of isolated MVS
from the Society of Thoracic Surgeons (STS) database:
2.3% versus 1.8% in the STS database. It is not surprising
that the overall rates of morbidity reported in our analysis of
the NIS are slightly higher than that reported in the most
recent STS analysis because we included both elective
and urgent cases. When isolated to elective cases, stroke
was similar: 1.02% versus 1.27% in the STS database,
and renal failure was similar: 2.0% versus 2.98% in the
STS database.14
Complications
Among patients undergoing isolated MVS, pneumonia
was the most common complication occurring in more
than 1 in 20 patients, and was associated with the second
largest risk-adjusted median net increase in hospital cost
and length of stay. Pneumonia also resulted in the single
greatest total expenditure, at approximately $25 million an-
nually. Sepsis and renal failure requiring dialysis, which
were comparable in their effect on hospital cost and length868 The Journal of Thoracic and Cardiovascular Surgof stay, resulted in the second and third greatest total expen-
diture, respectively. Of note, acute postoperative pulmonary
edema had a significant impact on total hospital costs of ap-
proximately $11,000, and therewas a significant association
between postoperative pulmonary edema and development
of pneumonia, emphasizing the impact of perioperative
management on postoperative resource use. These findings
support recent efforts dedicated to providing more aggres-
sive respiratory care and to lowering rates of infection
through quality improvement initiatives aimed at formaliz-
ing process-of-care measures.15,16 In addition, our results
are supported by a recent analysis of the STS database
demonstrating an increase in the incidence of prolonged
ventilation and pneumonia.5 Of note, cardiac tamponade
had the largest effect on total cost and length of stay, but it
had the lowest prevalence in our series.
In addition to the effect of specific complications on re-
source use, this analysis also demonstrates the multiplica-
tive effect of complications on total costs and length of
stay. Although there was a $21,000 difference in total cost
and an 8-day difference in length of hospitalization between
patients who had no complications and patients who had
1 complication, the difference increased to $44,964 and
14 days when the comparison was made against patients
with 2 complications. Thus, 2 complications added
$44,964 to the total cost of hospitalization, which is greater
than the median cost of admission at $35,446.
In total, these 8 complications were annually associated
with an additional $71.9 to $89.4 million in costs and an ad-
ditional 24,000 to 29,000 inpatient hospital days during the
index hospitalization alone. Although complications cannot
be avoided in many cases, these data highlight the signifi-
cant resources consumed when a patient experiences com-
plications postoperatively and demonstrate areas where
quality improvement initiatives may be directed to further
improve cost-effectiveness and patient outcomes.
Discharge Disposition
The time horizon of this analysis is limited to outcomes
during the index hospitalization. However, available dis-
charge disposition data suggest that complications have
an important impact on longer-term resource costs, both
direct and indirect. There was a significant correlation
between the discharge location and the presence of any
complication during the index hospitalization. Among pa-
tients experiencing no complications, 25.5% more patients
underwent routine home discharge compared with patients
who had 1 or more complication. In addition, patients who
had 1 or more complication were 17.4% more likely to be
discharged to a skilled nursing facility or intermediate care
facility, which clearly adds to long-term costs. These find-
ings highlight the importance of pursuing future studies
that explore the relationship between clinical outcomes
and quality of life, as well as the economic effects,ery c April 2012
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productivity. Furthermore, these findings suggest that pro-
viders should anticipate that patients who experience com-
plications are more likely to require additional care after
hospital discharge.
Therefore, further research that examines both hospital
charges and subsequent costs outside of standard home dis-
charge on the total economic burden of complications is
necessary. Although the NIS does not contain costing data
beyond the index hospitalization, there are other existing
data sources that may allow for better characterization of
intermediate and longer-term costs. For example, Thomp-
son-Reuters’ Marketscan Data,17 which include 43 million
covered lives, capture longitudinal data related to inpatient
and outpatient costs, as well as worker productivity data.
The University Health System Consortium data contain de-
tailed costing data from 90% of the academic centers na-
tionally and have the potential to be crossmatched with
detailed clinical data. Finally, physician-initiated state-
based quality groups, such as the Virginia Cardiac Surgery
Quality Initiative, contain uniquely detailed clinical and
economic data.
Limitations
There are several limitations to our analysis. First, the
NIS is an administrative database and does not contain
detailed clinical information on a variety of measures, in-
cluding the severity of mitral valve disease and history of
cardiac operations. Second, only 20% of nationwide insti-
tutions are sampled within the NIS; therefore, there exists
the potential for limitations in the number of hospitals sur-
veyed that perform comprehensive cardiac surgery. Third,
follow-up did not extend beyond the index hospitalization;
consequently, important events or complications that may
have occurred after discharge were not captured. Fourth,
the use of ICD-9 codes to identify clinical outcomes is
imperfect. There exists the potential for heterogeneity in re-
porting of adverse events among hospitals because data on
complications were extracted from ICD-9 codes rather than
protocol-defined end points as one would use in a prospec-
tive study. Such variability in reporting carries the potential
to introduce bias in outcome measures. However, use of
ICD-9 codes to assess clinical outcomes in administrative
registries is a well-established technique.7 In a series of
recent reports from the Complications Screening Project,
the validity of ICD-9-CM coding of several medical and
surgical complications was investigated. The coding of
surgical complications was found to be clinically valid.
When comparing ICD-9-CM coding and the clinical record,
the positive predictive value for complications varied
from 84.2% to 96.8% with kappa scores of 0.69 to
0.88.18,19 Furthermore, some important complications,
such as postoperative atrial fibrillation and sternal wound
infection, could not be identified. Finally, cost-to-chargeThe Journal of Thoracic and Caratios used in the analysis, and thus reported costs, may
be subject to bias because variability exists in state reporting
of cost-to-charge ratios (eg, variability in individual partici-
pating institutional ratios vs aggregate state ratios). Never-
theless, many of the limitations in this analysis must be
understood in the context of the strengths of the NIS, which
include its large size, representative quality, and standard-
ized methodology of survey.
Implications
Although instituting standardized process-of-care mea-
sures requires a significant institutional commitment, the
long-term benefits with regard to clinical outcomes and re-
source use cannot be underestimated. In addition, with new
policy measures such as the Hospital Inpatient Value-Based
Purchasing Initiative, hospitals will be placed under signif-
icant pressure to avoid such adverse events. Complications
have a significant and multiplicative effect on resource use
for index hospitalization. Complications also influence
long-term costs based on increased need for skilled nursing
and intermediate care placement on discharge, as well as
lost worker productivity. Although complications can
never be completely eliminated, pneumonia and sepsis,
for example, represent events that may benefit from efforts
at increased standardization of institutional process-of-care
measures to reduce these potentially preventable
complications.
In an era of increased national attention to cost effective-
ness and increased patient awareness of hospital reporting
of risk-adjusted outcomes, the current analysis not only
shows the impact of complications on resource use but
also serves as a starting point for quantifying the effect of
such complications and identifying areas of future improve-
ment and study.
CONCLUSIONS
In patients undergoing isolated MVS, postoperative
complications were associated with significant increases
in mortality, hospital costs, and length of stay. Among the
8 postoperative complications captured in this analysis,
pneumonia resulted in the greatest total additional cost
across the entire population of patients undergoing MVS,
followed by renal failure requiring dialysis and sepsis.
Further, stacking complications disproportionately in-
creased the related costs. In an era with growing national at-
tention to improving quality and containing costs, it is
important to understand the impact of complications on out-
comes and costs. This analysis may help drive quality im-
provement initiatives and improve cost-effectiveness, and
ultimately improve patient outcomes.
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Dr Richard J. Shemin (Los Angeles, Calif). I, too, want to
thank the Association for the opportunity to comment on this really
detailed and excellent study and presentation. The authors were
able to provide me with a detailed copy of the manuscript so I
have more information than was presented today.870 The Journal of Thoracic and Cardiovascular SurgThe fact that there is a price to pay for complications is well
known to this surgical community, but this study really met the
goal of quantifying the cost in dollars, days, and deaths, as well
as the postdischarge resource use after an isolated mitral valve sur-
gery. As the discussion clearly stated, this comes from an admin-
istrative data set, the Nationwide Inpatient Sample (NIS). This
sample is only 20% of nonfederal hospitals in 37 states and the
use of ICD-9 codes, as has been stated, has major limitations
and clearly does not allow a robust evaluation for risk adjustment
and other analyses that we are used to from the Society of Thoracic
Surgeons (STS) data base. The overall sample in this study was
taken from 2 years—2006 and 2007—more than 16,788 patients.
I was somewhat surprised to find that 10,000-plus patients actually
had concomitant procedures, leaving them with isolated mitral
valve surgery in 6297, and then I was also surprised to find 50%
of them actually had mitral valve repairs as opposed to replace-
ment. I am not sure we would have predicted that was the case.
The inpatient hospital mortality was actually quite good, 4% and
2% in elective cases, and 82% of the patients did not have any
of complications that were studied in this particular study. The
complication rates also of interest did not differ between repair
and tissue replacement or mechanical replacement and a single
complication clearly escalated the outcomes and the end points
such as mortality, length of stay, and cost, and the need for in-
creased resources. Very interesting was the exponential increase
in cost associated with multiple complications. I was really sur-
prised to find that pneumonia and sepsis were your most frequent
complications. I suspect this was because of the study design and
the choice of complications that you included in the study. These
potentially preventable complications can increase the cost of hos-
pitalization by more than $30,000. Cardiac tamponade, which was
the most costly complication in the study increasing the median
cost by $57,000, only occurred in 0.1% of the patients. Therefore,
I assume the ICD-9 codes were not capturing patients going back
to the operating room for bleeding, the use of blood utilization, and
as you mentioned the lack of studying atrial fibrillation, which is
very frequent, or sternal wound infection, which is infrequent
but very costly, is clearly a limitation. Therefore, I think this study
only looks at the tip of the iceberg as far as the true cost of com-
plications after isolated mitral valve surgery. Therefore, the study
challenges us to really improve on the strategies that we need to
incorporate to reduce the costs of taking care of our patients.
Therefore, I have 4 questions for you.
First, do you have any data on the impact of surgical volume at
these various hospitals, whether it be total cardiac surgery volume
or mitral valve surgery volume, on the frequency of the complica-
tions, or the cost?
Dr Iribarne. Thank you, Dr Shemin, for your careful and
thoughtful review of our manuscript.
First, regarding the quality of the data, NIS has a number of at-
tractive features. It is accessible, inexpensive, and easy to use.
Moreover, it contains information on the clinical and economic
data of the patient, as well as information on the institution. Fi-
nally, although crude, the use of ICD-9 codes to extract clinical
information from administrative datasets is a proven and increas-
ingly applied research approach.
However, we agree that this data has all of the limitations asso-
ciated with the use of large claims datasets. For example, as youery c April 2012
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by this analysis. Further, sepsis was likely overcoded and more
likely overlaps with other types of cardiovascular compromise
and pressor dependence.
Our group is exploring the use of other large data sources to pur-
sue similar questions to those proposed here. These might include
the Centers for Medicare and Medicaid Services (CMS), Thomp-
son-Reuters’ Marketscan data, the University Health System Con-
sortium (UHSC) data, and various statewide quality initiatives.
Finally, in the future, STS data may be linked to costing data,
and this may provide a powerful tool for pursuing these cost
questions.
With regard to the first question, it is possible to capture institu-
tional volume data in the NIS. Other groups have done this and, in
fact, we have explored questions using this data. However, for this
analysis, we did not explore the relationship between volume cost.
I think that this is, however, an important but complex group of
questions that are worth exploring.
Dr Shemin. Clearly, if one does find that to be the case as we
find in many other areas of surgery, you can incorporate and find
best practices that can be taught to others as we look for ways to
find solutions.
The second question has to do with whether or not there is any-
thing in your data set that will allow you to predict the 15% of pa-
tients who would have the complications that you showed us so
that strategies can be targeted to those patients and specific com-
plications and not have a very expensive protocol to try to incorpo-
rate everyone?
Dr Iribarne. Defining the relationship between preoperative
comorbidities and outcomes, including complications and cost,
is possible with this data. We have previously explored this in other
populations, including a single institution’s series of ventricular
assist device patients. We are also interested in exploring the use-
fulness of various severity or comorbid illness tools, including theThe Journal of Thoracic and CaDeyo modification to the Charlston index, the Elixhauser index,
and the 3M APR-DRG, to pursue other questions related to vol-
ume-outcome relationships across levels of patient risk and com-
paring disease-specific therapeutic options across various patient
risk strata.
Dr Shemin. And I have a methodologic question. When you
went ahead and looked at the 20% costs and then you looked at
the total costs by increasing it by a factor of 5, is that technically
correct? As I understand it, there are actually correction values
that come with the nationwide sample that allow you to look at
the total cohort and not necessarily do some arithmetic by increas-
ing 20% to 100% by just multiplying by 5.
Dr Iribarne.You are correct. The NIS assigns a correction fac-
tor to each patient and institution. The cost estimates that we pre-
sented were ranges based on bootstrapped estimates. Therefore,
the estimates are unlikely to differ significantly. Nevertheless,
per your suggestion, the final version of the manuscript uses an
NIS-provided correction factor to calculate this estimate.
Dr Shemin. The final question is, now that you have these data,
what types of things do you think we need to do to reduce this com-
plication rate and better treat these patients?
Dr Iribarne. Thank you for your question. This analysis alone
does nothing to improve outcomes or decrease costs. However, we
hope that it highlights opportunities for improving outcomes, de-
creasing costs, and therefore offering greater value in health
care. As you suggested earlier, as a health care community, we
need to be more aggressive by identifying best practices. We ap-
plaud these efforts, particularly of surgeon-driven statewide efforts
to improve quality, including those in Northern New England, Vir-
ginia, and Washington State. We hope that other regions adopt
similar methods. Further we see an opportunity for similar contin-
uous quality improvement efforts to be based on specific therapies,
such as transplantation, ventricular assist devices, and valvular
therapies.rdiovascular Surgery c Volume 143, Number 4 871
APPENDIX 1. Univariate analysis of baseline characteristics
Baseline variable No complication Any complication P value
Demographics
Age 56.7  0.27 60.4  0.51 <.001
Male 2,535 (48.9%) 527 (48.4%) .941
Elective procedure 3,650 (70.3%) 453 (41.6%) <.001
Primary payer: Medicare 1,975 (38.1%) 583 (53.5%) <.001
Primary payer: Private 2,460 (47.4%) 321 (29.5%) <.001
Comorbidities
Peripheral vascular disease 1,842 (35.5%) 564 (51.8%) <.001
Heart failure 1,839 (35.4%) 557 (51.2%) <.001
Chronic obstructive pulmonary disease 836 (16.1%) 228 (20.9%) <.001
History of any malignancy 840 (16.2%) 106 (9.7%) <.001
Diabetes mellitus 556 (10.7%) 114 (10.5%) .811
Chronic kidney disease 329 (6.3%) 242 (22.2%) <.001
Cerebrovascular disease 182 (3.5%) 195 (17.9%) <.001
Previous myocardial infarction 195 (3.8%) 24 (2.2%) .011
Rheumatologic disease 113 (2.2%) 29 (2.7%) .327
Diabetes with chronic complications 50 (0.96%) 32 (2.9%) <.001
Moderate or severe liver dysfunction 50 (0.96%) 32 (2.9%) <.001
Peptic ulcer disease 0 45 (4.13%) <.001
Mild liver dysfunction 20 (0.39%) 10 (0.92%) .020
Hemiplegia or paraplegia 9 (0.17%) 14 (1.3%) .37
Metastatic solid tumor 10 (0.19%) 4 (0.37%) .267
Human immunodeficiency virus 7 (0.13%) 6 (0.55%) .006
Dementia 2 (0.04%) 0 .517
APPENDIX 2. Length of stay, total hospitalization costs, and frequency of any in-hospital complication by procedure type
Procedure type Frequency Percent Median LOS (d) Median total cost ($) In-hospital complication frequency %
Isolated mMVR 1732 10.32 9 39,464 377 2.25
mMVRþAVR 445 2.65 11 50,600 109 0.65
mMVRþCABG 776 4.62 12 47,600 334 1.99
mMVRþMAZE 531 3.16 9 38,491 65 0.39
mMVRþother 605 3.6 13 54,100 190 1.13
Isolated MVr 3283 19.56 6 30,967 359 2.14
MVrþAVR 637 3.79 10 44,926 156 0.93
MVrþCABG 2773 16.52 11 43,200 1290 7.68
MVrþCABGþAVR 480 2.86 11 50,618 178 1.06
MVrþCABGþMAZE 613 3.65 11 45,753 201 1.20
MVrþMAZE 1022 6.09 8 36,432 117 0.70
MVrþother 290 1.73 10 47,600 65 0.39
Isolated tMVR 1282 7.64 11 44,850 358 2.13
tMVRþAVR 374 2.23 13 54,646 118 0.70
tMVRþCABG 861 5.13 12 50,800 368 2.19
tMVRþCABGþAVR 250 1.49 14 66,683 88 0.52
tMVRþCABGþAVRþTVR 3 0.02 14 49,000 1 0.01
tMVRþMAZE 435 2.59 10 43,228 76 0.45
tMVRþother 396 2.36 12 54,047 121 0.72
Total procedures ¼ 16,788
MVr,Mitral valve replacement; mMVR, mechanical mitral valve replacement; tMVR, tissue mitral valve replacement; TVR, tricuspid valve replacement; CABG, coronary artery
bypass grafting; LOS, length of stay; AVR, aortic valve replacement. All percentages reported use total procedures (n ¼ 16,788) as the denominator.
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